Emerging role and therapeutic implications of p53 in intervertebral disc degeneration

作者：Yidian Wang, Shou‐Ye Hu, Weisong Zhang, Bin-Fei Zhang, Zhi Yang · 发表于：Cell Death Discovery · 年份：2023 · DOI：10.1038/s41420-023-01730-5 · 被引用次数：17 · 研究领域：Spine and Intervertebral Disc Pathology、Management of metastatic bone disease、Healthcare and Venom Research

Lower back pain (LBP) is a common degenerative musculoskeletal disease that imposes a huge economic burden on both individuals and society. With the aggravation of social aging, the incidence of LBP has increased globally. Intervertebral disc degeneration (IDD) is the primary cause of LBP. Currently, IDD treatment strategies include physiotherapy, medication, and surgery; however, none can address the root cause by ending the degeneration of intervertebral discs (IVDs). However, in recent years, targeted therapy based on specific molecules has brought hope for treating IDD. The tumor suppressor gene p53 produces a transcription factor that regulates cell metabolism and survival. Recently, p53 was shown to play an important role in maintaining IVD microenvironment homeostasis by regulating IVD cell senescence, apoptosis, and metabolism by activating downstream target genes. This study reviews research progress regarding the potential role of p53 in IDD and discusses the challenges of targeting p53 in the treatment of IDD. This review will help to elucidate the pathogenesis of IDD and provide insights for the future development of precision treatments.